Tamoxifen found to reduce breast cancer rates by 30%
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arimidex, NICE, anastrozole, astrazenea, breast cancer, tamoxifen
A study from Queen Mary University has demonstrated that tamoxifen can reduce breast cancer rates by around 30% over 20 …
Half of England on prescription drugs
December 11, 2014Sales and Marketing England, HSCIC, NHS, doctors, prescribing, prescriptions
Almost half of the people in England are taking regular prescription medicines according to a new report by the Health …
Kim Lemon named head of Liberation Unlimited
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Creston Health, kim lemon, liberation unlimited
Marketing communications agency Liberation Unlimited has appointed Kim Lemon to head its operations. Since the UK-based comms firm joined the …
Treatment shifts away from chemotherapy for multiple myeloma
December 10, 2014Research and Development, Sales and Marketing Kyprolis, carfilzomib, chemotherapy, myeloma, onyx pharmaceuticals
Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …
Private firms account for a third of NHS contracts
December 10, 2014Medical Communications, Sales and Marketing Budget, Cameron, Hunt, NHS, Osborne, autumn, election, privatisation
A large percentage of NHS contracts in England have been awarded to private sector providers since 2013, according to data …
Labour to extend cancer drugs funding if elected
December 10, 2014Research and Development, Sales and Marketing CDF, Cancer, Labour, NHS, NICE, andy burnham, election
Labour has committed to continuing the Cancer Drugs Fund system under the guise of a new £330 million ‘Cancer Treatment …
EFPIA gives president role to Novartis chief executive
December 10, 2014Medical Communications, Sales and Marketing EFPIA, Novartis, Sanofi, Witty, garidel, joe jimenez, oschmann
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has named Novartis chief executive Joe Jimenez as its new president. …
Pharnext adds industry veteran to board
December 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Michel de Rosen, pharnext
France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors. For nearly 25 years …
AstraZeneca constipation drug gets EU nod
December 9, 2014Sales and Marketing AstraZeneca, KODIAC, NKTR-118, PAMORA, moventig, naloxegol
AstraZeneca’s opioid-induced constipation drug Moventig has been approved by the European Commission. The first once-daily PAMORA tablet to be given …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
Mixed results for new leukaemia drugs
December 9, 2014Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib
Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …
Novartis biosimilar rivals Amgen offering
December 9, 2014Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, filgrastim, zarzio
An investigational biosimilar by Novartis’ generic pharma arm Sandoz has been found to have comparable safety and efficacy readings to …
Ranbaxy and Sun Pharma merger approved
December 9, 2014Manufacturing and Production, Sales and Marketing FDA, Ranbaxy, Sun Pharma, cci, tamsulosin, tolterodine
The Competition Commission of India (CCI) has approved Sun Pharma’s acquisition of struggling drugmaker Ranbaxy, subject to conditions designed to …
Pfizer buys into gene therapy
December 9, 2014Research and Development, Sales and Marketing London, Pfizer, gene therapy, haemophilia, spark, therapeutics
Pfizer has announced that it is establishing a gene therapy platform as it looks to expand its rare diseases operations. …
Celgene appoints new UK general manager
December 9, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Wim Souverijns
Celgene has appointed Wim Souverijns as its new vice president and general manager for UK and Ireland. Souverijns (pictured) takes …
AZ triumphs in Nexium pay-for-delay trial
December 8, 2014Sales and Marketing AstraZeneca, Dr Reddy's, Nexium, Ranbaxy, dr reddys, esomeprazole
AstraZeneca and Ranbaxy have avoided what might have been a $10 billion pay out regarding delays to the generic version …
Updated: Merck buys antibiotics specialist Cubist
December 8, 2014Sales and Marketing Antibiotics, Merck, Novartis, cubicin, cubist, eumer
Merck has purchased US antibiotics maker Cubist in a deal valued at $9.5 billion. The acquisition values Cubist at around …
Blackberry creates cancer diagnostic tool
December 8, 2014Medical Communications, Sales and Marketing Blackberry, chen, diagnostic, nanthealth, passport, soon-shiong
Canadian smartphone maker Blackberry is entering the healthcare arena with a cancer diagnostic tool aimed at doctors and nurses. Via …
Merck and Galderma breach ABPI code
December 8, 2014Medical Communications, Sales and Marketing ABPI, Erbitux, Galderma, PMCPA, merch
Merck Serono and Galderma will be named in advertisements as guilty of the most serious breach of the ABPI Code …
Analysis finds no Actos bladder cancer link
December 8, 2014Sales and Marketing Actos, Cancer, Takeda, bladder, lilly, pioglitazone, type 2
A large-scale analysis of patient data has found that pioglitazone, the diabetes drug that is the subject of ongoing safety …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
